What Is the Best Obesity Drug in 2026?
A data-driven comparison of every major approved and investigational obesity drug — ranked by weight loss, mechanism, approval status, and route of administration. Eight drugs. One table. All the data.
Update History ▾
Initial publication
As of March 2026, tirzepatide (Zepbound) is the most effective FDA-approved obesity drug at 22.5% weight loss in the SURMOUNT-1 trial. In clinical trials, retatrutide leads all drugs at 28.7% but is not yet approved. The best choice depends on availability, route preference, and individual factors. For researchers tracking the full pipeline, this page compares all eight leading compounds side by side.
Janoshik-verified, HPLC ≥99.2% purity. Retatrutide Pen 30 mg from AED 1,000/pen. Ships from Dubai.
- Tirzepatide (Zepbound) is the most effective FDA-approved obesity drug — 22.5% weight loss in SURMOUNT-1 at 72 weeks.
- Retatrutide leads all clinical trial candidates at 28.7% weight loss in TRIUMPH-4, but is not yet approved.
- CagriSema filed for NDA in December 2025, with 22.7% weight loss vs placebo in REDEFINE 1 — a potential third major option.
- Three oral options are emerging: the approved Wegovy pill (16.6%), plus investigational orforglipron (12.4%) and oral VK2735 (12.2%).
- Multiple Phase 3 readouts and regulatory decisions expected throughout 2026 will reshape the competitive landscape.
What Is the Most Effective Obesity Drug Right Now?
Among FDA-approved obesity drugs, tirzepatide (Zepbound) holds the strongest weight-loss data. In the SURMOUNT-1 trial, the highest dose (15 mg weekly) produced 22.5% average weight loss at 72 weeks versus 2.4% for placebo. Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for chronic weight management in November 2023.
The next most effective approved option is semaglutide (Wegovy), a GLP-1-only agonist from Novo Nordisk. Wegovy showed 16.9% weight loss in the STEP 1 trial at 68 weeks. Wegovy was the first GLP-1 approved specifically for obesity (June 2021) and has accumulated the broadest real-world data of any drug in this class.
In 2025, Novo Nordisk also gained FDA approval for the Wegovy pill (oral semaglutide 25 mg), which showed 16.6% weight loss in the OASIS 4 trial. This is the first oral GLP-1 approved for obesity, offering an alternative for patients who prefer not to inject. For a detailed comparison, see Oral Obesity Drugs in 2026.
What About Drugs Still in Clinical Trials?
The investigational drug with the highest weight-loss figure in any Phase 3 trial is retatrutide, Eli Lilly’s triple agonist (GLP-1/GIP/glucagon receptor). In the TRIUMPH-4 Phase 3 trial, retatrutide produced 28.7% average weight loss at 68 weeks — the highest reported figure for any obesity drug in a registrational trial. Retatrutide is not yet approved and remains in Phase 3 development. For dosing protocols and titration schedules, see the retatrutide dosage guide. For adverse event data including the dysesthesia signal, see our retatrutide side effects profile.
CagriSema, Novo Nordisk’s co-formulation of cagrilintide (amylin analog) and semaglutide (GLP-1), is the closest to market among pipeline drugs. The REDEFINE 1 trial showed 22.7% weight loss versus placebo at 68 weeks, and Novo Nordisk filed a New Drug Application in December 2025. In the head-to-head REDEFINE 4 trial, CagriSema demonstrated 20.2% weight loss compared to tirzepatide. See Is CagriSema Approved? for the latest status.
Survodutide, a dual GLP-1/glucagon receptor agonist from Boehringer Ingelheim, showed approximately 19% weight loss in a Phase 2 study at 46 weeks. Phase 3 trials are ongoing. Survodutide is also being studied for MASH (metabolic dysfunction-associated steatohepatitis), which may differentiate it from other obesity drugs. See Is Survodutide Approved? for details.
| # | Drug | Mechanism | Route | Best WL % | Trial | Status | Developer |
|---|---|---|---|---|---|---|---|
| 1 | Retatrutide | Triple agonist (GLP-1/GIP/GCGR) | Injectable | 28.7% | TRIUMPH-4, 68wk | Phase 3 | Eli Lilly |
| 2 | CagriSema | Amylin + GLP-1 | Injectable | 22.7% | REDEFINE 1, 68wk | NDA Filed | Novo Nordisk |
| 3 | Tirzepatide (Zepbound) | Dual GIP/GLP-1 | Injectable | 22.5% | SURMOUNT-1, 72wk | FDA Approved | Eli Lilly |
| 4 | Survodutide | Dual GLP-1/glucagon | Injectable | ~19% | Phase 2, 46wk | Phase 3 | Boehringer Ingelheim |
| 5 | Semaglutide (Wegovy) | GLP-1 agonist | Injectable | 16.9% | STEP 1, 68wk | FDA Approved | Novo Nordisk |
| 6 | Oral Semaglutide (Wegovy pill) | GLP-1 agonist (oral) | Oral | 16.6% | OASIS 4 | FDA Approved | Novo Nordisk |
| 7 | Orforglipron | Non-peptide GLP-1 agonist | Oral | 12.4% | ATTAIN-1, 72wk | Phase 3 | Eli Lilly |
| 8 | Oral VK2735 | GLP-1 agonist (oral) | Oral | 12.2% | Phase 2, 13wk | Phase 2 | Viking Therapeutics |
How Do Approved vs Pipeline Drugs Compare?
The gap between approved and investigational drugs is significant. The most effective approved drug, tirzepatide, produces 22.5% weight loss. The leading pipeline drug, retatrutide, reaches 28.7% — a 6.2 percentage-point difference that represents meaningful additional weight reduction. For a full three-way efficacy comparison, see Retatrutide vs Tirzepatide vs CagriSema. For a direct injectable-vs-oral comparison, see Retatrutide vs Orforglipron.
However, approval status matters. Tirzepatide and semaglutide are commercially available with established safety profiles from large post-marketing populations. Pipeline drugs like retatrutide and survodutide still carry the uncertainty of ongoing trials and regulatory review. CagriSema occupies a middle ground — strong Phase 3 data with an NDA already filed.
The practical implication: for approved options today, tirzepatide (Zepbound) offers the highest efficacy. For researchers tracking the pipeline, retatrutide represents the ceiling of what next-generation obesity drugs might deliver. Track all timelines on the Obesity Drug Approval Tracker 2026.
What About Oral Options?
Three oral obesity drugs define the landscape in 2026, each with a distinct profile:
Wegovy pill (oral semaglutide 25 mg) — FDA-approved in 2025, 16.6% weight loss in OASIS 4. It builds on the Rybelsus oral semaglutide platform, a peptide-based oral GLP-1 that requires fasting conditions: empty stomach, limited water, and a 30-minute wait before eating. Despite these restrictions, it is the first and only approved oral GLP-1 for obesity.
Orforglipron — Eli Lilly’s non-peptide oral GLP-1 agonist. Phase 3 ATTAIN-1 data showed 12.4% weight loss at 72 weeks. The key advantage is no food or water dosing restrictions, which could improve real-world adherence. Not yet approved; no FDA submission date disclosed.
Oral VK2735 — Viking Therapeutics’ oral GLP-1 agonist. Phase 2 data showed 12.2% weight loss at just 13 weeks, a shorter trial duration that makes direct comparison difficult but suggests strong potency. Still in early-stage development.
For a detailed breakdown of all three compounds, see Oral Obesity Drugs in 2026 and our Wegovy price and dosing guide for the UAE.
What About Drugs for Specific Conditions?
Several obesity drugs are being studied for conditions beyond weight loss alone, which may influence treatment selection depending on comorbidities:
MASH (metabolic dysfunction-associated steatohepatitis): Survodutide is the leading candidate, with its dual GLP-1/glucagon mechanism showing particular promise for liver fat reduction in clinical trials. The glucagon receptor component may provide additional metabolic benefits relevant to MASH. See survodutide’s full profile for details.
Obstructive sleep apnea (OSA): Tirzepatide (Zepbound) received an FDA approval for moderate-to-severe OSA in December 2024, making it the first obesity drug with this specific indication. This is a meaningful differentiator for patients with both conditions.
Osteoarthritis (OA): Retatrutide is being studied in the TRIUMPH clinical program for effects on knee osteoarthritis. The substantial weight loss (28.7%) may produce meaningful joint-related benefits, though dedicated OA data are still emerging. Beyond weight, body composition and muscle mass preservation are increasingly important outcomes across all these compounds.
REDEFINE 4: What Does CagriSema vs Tirzepatide Mean?
The REDEFINE 4 trial is one of the few head-to-head comparisons between leading obesity drugs. CagriSema demonstrated 20.2% weight loss in this trial, compared directly against tirzepatide. This result positioned CagriSema as competitive with the current best-approved drug, strengthening Novo Nordisk’s case for regulatory approval.
For context, CagriSema’s placebo-adjusted result from REDEFINE 1 was 22.7%, while the head-to-head REDEFINE 4 figure of 20.2% reflects a different trial design (active comparator rather than placebo). The key takeaway: CagriSema is in the same efficacy tier as tirzepatide, with a different mechanism of action (amylin + GLP-1 vs GIP + GLP-1). See CagriSema vs Tirzepatide for the full breakdown.
What Should Researchers Watch in 2026?
Several catalysts in 2026 could reshape the obesity drug landscape. Here are the key events to track:
- H1 2026 CagriSema FDA review decision — NDA filed December 2025. An approval would make CagriSema the third major injectable obesity drug alongside Wegovy and Zepbound.
- 2026 Retatrutide TRIUMPH program readouts — additional Phase 3 data expected, including results in type 2 diabetes and potentially osteoarthritis indications.
- 2026 Orforglipron ATTAIN program updates — additional Phase 3 results in obesity and type 2 diabetes. FDA submission timeline may become clearer.
- 2026 Survodutide Phase 3 readouts — data expected from the ACHIEVE obesity program and MASH-focused studies. Could establish survodutide’s dual positioning.
- 2026 Oral VK2735 Phase 2b/3 progress — Viking Therapeutics advancing toward later-stage trials. Longer-duration weight-loss data needed.
- Ongoing Real-world data accumulation — post-marketing studies for tirzepatide, semaglutide, and oral semaglutide continuing to build long-term safety and adherence evidence.
For a comprehensive timeline of every upcoming regulatory decision, data readout, and Phase 3 milestone, see the Obesity Drug Approval Tracker 2026 and the Obesity Drug Pipeline Timeline. For a ranked comparison of verified research peptide suppliers, see our best research peptides 2026 guide.
Our Research Standards
This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →
- Eli Lilly. Retatrutide Phase 3 TRIUMPH-4 results — 28.7% weight loss at 68 weeks. investor.lilly.com
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. SURMOUNT-1. N Engl J Med. 2022;387(3):205–216. nejm.org
- Novo Nordisk. CagriSema REDEFINE 1 Phase 3 results — 22.7% weight loss vs placebo. novonordisk.com
- Novo Nordisk. CagriSema NDA filing, December 2025. novonordisk.com
- Novo Nordisk. CagriSema REDEFINE 4 head-to-head vs tirzepatide — 20.2% weight loss. novonordisk.com
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. STEP 1. N Engl J Med. 2021;384(11):989–1002. nejm.org
- Novo Nordisk. FDA approves Wegovy pill (oral semaglutide 25 mg). 2025. novonordisk.com
- Eli Lilly. Orforglipron Phase 3 ATTAIN-1 results — 12.4% weight loss at 72 weeks. August 2025. investor.lilly.com
- Viking Therapeutics. Oral VK2735 Phase 2 results — 12.2% weight loss at 13 weeks. vikingtherapeutics.com
- Boehringer Ingelheim. Survodutide Phase 2 obesity data — approximately 19% weight loss at 46 weeks. boehringer-ingelheim.com
- FDA. Zepbound (tirzepatide) approval for obstructive sleep apnea. December 2024. fda.gov
Retatrutide Pen 30 mg
99.262% HPLC purity, Janoshik Analytical. 300 clicks per pen, ships from Dubai.
Order Retatrutide Pen →